奥氮平与利培酮对精神分裂症患者生活质量影响的对照研究

A Controlled Study of Influence of Olanzapine and Risperidone on Life Quality of Schizophrenia Patients

目的评价国产奥氮平与利培酮治疗精神分裂症的疗效、安全性及其对患者生活质量的影响。方法将78例首发精神分裂症患者随机分为奥氮平组和利培酮组,各39例,治疗8周,采用阳性与阴性症状量表(PANSS)、不良反应量表(TESS)、生活质量综合评定问卷(GQOLI)分别评定患者的疗效及生活质量。结果两组PANSS总分治疗后均明显下降(P<0.01),组间差异则无显著性(P>0.05)。奥氮平组的显效率为66.67%、有效率为84.62%,利培酮组的显效率为61.54%、有效率为82.05%,两组比较无显著性差异(P>0.05)。两组GQOLI评分治疗8周末除物质生活维度无显著性变化外,其他各维度评分均显著性提高(P<0.05),而组间生活质量4个维度评分亦无显著性差异(P>0.05)。两组不良反应发生率低且程度轻,奥氮平组体重增加比例较高,而利培酮组锥体外系反应比例较高。结论奥氮平和利培酮对精神分裂症均有显著疗效,安全性高,能较好地提高患者的生活质量。

Objective To evaluate the efficacy and safety of domestic olanzapine and risperidone in the treatment of schizophrenia and their influence on the life quality of schizophrenia patients. Methods Seventy- eight cases of first episode schizophrenia were random- ized into the olanzapine group and the rispcridone group（39 cases each） with 8-week treatment. The Positive and Negative Syndrome Scale （PANSS）, the Treatment Emergent Symptom Scale （TESS）, the General Quality of Life Inventory （GQOLI） were adopted to assess the efficacy and the life quality of the patients. Results The PANSS total scores which after treatment were significantly decreased （P〈0. 01）, there was no statistical difference between 2 groups（ P 〉0. 05）. The excellent rate and the effective rate were 66.67% and 84. 62% in the olauzapine group, which were 61.54% and 82.05% in the risperidone group, the difference between 2 groups showing no statistical significance （P 〉 0. 05）. The GQOLI scores,the other dimensionalities scores of GQOLI scores except the material-life di- mensionality after 8- week treatment were significantly improved than before treatment （P 〈 0.05）, and the 4 dimensionalities scores of the quality of life also had no statistical difference between 2 groups （P 〉 0.05）. Two groups both had the low incidence rate and the slight degree of adverse reactions. The olanzapine group had a higher proportion of weight gain, while the risperidone group had a higher proportion of extrapyramidal reactions. Conclusion Olanzapine and risperidone both have significant efficacy and high security for treating schizophrenia, and preferably improve the quality of life of the patients.